NEW YORK, November 15, 2017 /PRNewswire/ --
If you want a Stock Review on SGYP, NVO, UTHR, or DEPO then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com redirects investors' attention to the Drug Manufacturers space, which comprises of companies that manufacture and process pharmaceutical
New York headquartered Synergy Pharmaceuticals Inc.'s shares saw a drop of 16.80%, finishing Tuesday's trading session at $2.03. A total volume of 27.37 million shares was traded, which was higher than their three months average volume of 5.78 million shares. The stock is trading below its 50-day moving average by 29.50%. Moreover, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have a Relative Strength Index (RSI) of 25.88.
On November 13th, 2017, Synergy Pharma announced the pricing of its underwritten offering of 21,705,426 shares of the Company's common stock, together with accompanying warrants to purchase an aggregate of 21,705,426 shares of common stock at a combined price to the public of $2.58 per share and accompanying warrant. The aggregate offering price, before deducting underwriting discounts and commissions and other offering expenses, is expected to be approximately $56 million. Free research report on SGYP is available at:
On Tuesday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 1.07 million shares, and ended the session 0.16% higher at $49.84. The stock has gained 1.05% in the last one month, 7.39% over the previous three months, and 38.98% on an YTD basis. The Company's shares are trading 1.47% above their 50-day moving average and 18.62% above their 200-day moving average. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 52.43.
On October 18th, 2017, Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the US FDA voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type-2 diabetes. One member of the committee abstained. The recommendation for approval was based on data from SUSTAIN, a comprehensive global development program that evaluated the safety and efficacy of semaglutide, administered once-weekly. The complimentary research report on NVO can be downloaded at:
Shares in Silver Spring, Maryland headquartered United Therapeutics Corp. closed at $118.58, slightly down 0.98% from the last trading session. The stock recorded a trading volume of 312,325 shares. The Company's shares are trading 2.20% below their 50-day moving average. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 44.62.
On October 23rd, 2017, United Therapeutics announced approval by the US FDA of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution. Designed based on patient and physician feedback, the new device has a cleaner, more ergonomic design that includes single-button operation; an intuitive user interface for adjusting breath counts; a color, graphical display that leads patients through the inhalation process and displays time since last treatment; and an internal, rechargeable battery. Visit DailyStockTracker.com today and access our complete research report on UTHR at:
Newark, California headquartered Depomed Inc.'s stock ended 5.61% lower at $6.06. A total volume of 2.39 million shares was traded, which was above their three months average volume of 1.49 million shares. The Company's shares have advanced 19.76% in the last one month. The stock is trading above its 50-day moving average by 7.03%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 58.12.
On November 07th, 2017, Depomed announced that it has entered into an agreement with Slán Medicinal Holdings Limited ("Slán") under which Depomed will acquire from Slán rights to market the specialty drug, cosyntropin (Synthetic ACTH Depot) in the US and divest its Lazanda® (fentanyl) nasal spray CII to Slán.
On November 09th, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Underweight' to 'Equal-Weight'. Get free access to your research report on DEPO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Kleine Levin (KLS) or sleeping beauty syndrome is a rare neurological disorder that primarly ...
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...View All